Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|CALGB-90104||CALGB||A Randomized Phase III Study Comparing Sequential Chemotherapy (AG-TP) to Cisplatin and Gemcitabine as Adjuvant Treatment After Cystectomy for Transitional Cell Carcinoma of the Bladder||Adult CIRB - Late Phase Emphasis||Completed|
|E2805||ECOG||ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-HN007||NRG||An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-34||NSABP||A Clinical Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-0825||RTOG||Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma||Adult CIRB - Late Phase Emphasis||Completed|
|NRG-GI005||NRG||Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0221||SWOG||Phase III Trial of Continuous Schedule AC+G Vs. Q2 Week Schedule AC; Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY016||NRG||A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0240||GOG||A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865; IND #113912) Versus the Non-Platinum Doublet; Topotecan Plus Paclitaxel; with and without NCI-Supplied Bevacizumab; in Stage IVB; Recurrent or Persistent Carcinoma of the Cervix||Adult CIRB - Late Phase Emphasis||Completed|
|C80405||CALGB||A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab; or Cetuximab (C225); or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum||Adult CIRB - Late Phase Emphasis||Available to Open|